Details of the Drug

General Information of Drug (ID: DMDXZ6O)

Drug Name
ALK-001
Indication
Disease Entry ICD 11 Status REF
Age-related macular degeneration 9B75.0 Phase 2 [1]
Stargardt disease 9B70 Phase 2 [2]
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C22H32O2
Canonical SMILES
CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CCOC(=O)C)C)C
InChI
InChI=1S/C22H32O2/c1-17(9-7-10-18(2)14-16-24-20(4)23)12-13-21-19(3)11-8-15-22(21,5)6/h7,9-10,12-14H,8,11,15-16H2,1-6H3/b10-7+,13-12+,17-9+,18-14+/i2D3
InChIKey
QGNJRVVDBSJHIZ-QJZZLBIKSA-N
Cross-matching ID
PubChem CID
126843217
TTD ID
D0B9RD
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT02402660) Tolerability and Effects of ALK-001 on Stargardt Disease. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)